Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Has Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Sugemalimab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms GEMSTONE-301
- Sponsors Cornerstone Pharmaceuticals Inc; CStone Pharmaceuticals
- 14 Jun 2023 Status changed from active, no longer recruiting to completed.
- 10 Nov 2022 According to EQRx media release, an interim analysis of OS from this pivotal Phase 3 GEMSTONE-301 trial of sugemalimab in Stage III NSCLC is expected in 2023.
- 09 Aug 2022 Results of pre-planned PFS final analysis, and a preliminary results of OS presented at the 2022 World Conference on Lung Cancer